Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade
diseaseOn this page
Also known as carcinoid tumor of small intestinecarcinoid tumour of small intestinesmall intestinal NETsmall intestinal neuroendocrine tumorsmall intestinal neuroendocrine tumoursmall intestinal well differentiated endocrine tumorsmall intestinal well differentiated endocrine tumor/carcinomasmall intestinal well differentiated endocrine tumoursmall intestine neuroendocrine tumorsmall intestine neuroendocrine tumour
Summary
Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade (MONDO:0002995) is a cancer (an umbrella term covering 6 Mondo subtypes) and 4 clinical trials. Top therapeutic interventions include telotristat ethyl, lanreotide, and surufatinib. A subtype of digestive system neuroendocrine tumor, grade 1/2 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | small intestine neuroendocrine tumor, well differentiated, low or intermediate grade |
| Mondo ID | MONDO:0002995 |
| NCIT | C96061 |
| UMLS | C3272528 |
| MedGen | 474161 |
| GARD | 0023316 |
| Anatomy (UBERON) | UBERON:0002108 |
| Is cancer (heuristic) | yes |
Also known as: carcinoid tumor of small intestine · carcinoid tumour of small intestine · small intestinal NET · small intestinal neuroendocrine tumor · small intestinal neuroendocrine tumour · small intestinal well differentiated endocrine tumor · small intestinal well differentiated endocrine tumor/carcinoma · small intestinal well differentiated endocrine tumour · small intestine neuroendocrine tumor · small intestine neuroendocrine tumour
Disease family
This is a subtype of digestive system neuroendocrine tumor, grade 1/2. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › small intestine neuroendocrine tumor, well differentiated, low or intermediate grade
Related subtypes (9): gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, gallbladder neuroendocrine tumor, grade 1/2, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1
Subtypes (6): small intestinal neuroendocrine tumor G1, small intestinal vasoactive intestinal peptide producing tumor, small intestinal L-cell glucagon-like peptide producing tumor, duodenal neuroendocrine tumor, well differentiated, low or intermediate grade, jejunal neuroendocrine tumor, well differentiated, low or intermediate grade, ileal neuroendocrine tumor, well differentiated, low or intermediate grade
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04065165 | PHASE3 | WITHDRAWN | Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome |
| NCT04579679 | PHASE2 | TERMINATED | Open-Label Surufatinib in European Patients With NET |
| NCT03442959 | Not specified | UNKNOWN | Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN |
| NCT05246319 | Not specified | COMPLETED | Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TELOTRISTAT ETHYL | 4 | 2 |
| LANREOTIDE | 4 | 1 |
| SURUFATINIB | 3 | 1 |
Related Atlas pages
- Drugs: Telotristat Ethyl, Lanreotide, Surufatinib